@article{10902/26815,
year = {2022},
month = {10},
url = {https://hdl.handle.net/10902/26815},
abstract = {Background: The comparative effectiveness of transradial (TRA) compared with transfemoral (TFA) access in acute coronary syndrome (ACS) patients undergoing complex percutaneous coronary intervention (PCI) remains unclear.

Methods: Among 8404 ACS patients in the Minimising Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX)-Access trial, 5233 underwent noncomplex (TRA: n = 2590; TFA: n = 2643) and 1491 complex (TRA: n = 777; TFA: n = 714) PCI. Co-primary outcomes were major adverse cardiovascular events (MACE, the composite of all-cause mortality, myocardial infarction, or stroke) and the composite of MACE and Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding (net adverse cardiovascular events [NACE]) at 30 days.

Results: Rates of 30-day MACE (HR 0.94, 95% CI 0.72-1.22) or NACE (HR 0.89, 95% CI 0.69-1.14) did not significantly differ between groups in the complex PCI group, whereas both primary end points were lower (HR 0.84, 95% CI 0.70-1.00; HR 0.83, 95% CI 0.70-0.98; respectively) with TRA among noncomplex PCI patients, with negative interaction testing (Pint = 0.473 and 0.666, respectively). Access-site BARC type 3 or 5 bleeding was lower with TRA, consistently among complex (HR 0.18, 95% CI 0.05-0.63) and noncomplex (HR 0.41, 95% CI 0.20-0.85) PCI patients, whereas the former group had a greater absolute risk reduction of 1.7% (number needed to treat: 59) owing to their higher absolute risk.

Conclusions: Among ACS patients, PCI complexity did not affect the comparative efficacy and safety of TRA vs TFA, whereas the absolute risk reduction of access-site major bleeding was greater with TRA compared with TFA in complex as opposed to noncomplex PCI.},
publisher = {Elsevier},
publisher = {Can J Cardiol
. 2022 Oct;38(10):1488-1500},
title = {Radial vs Femoral Access in ACS Patients Undergoing Complex PCI Is Associated With Consistent Bleeding Benefit and No Excess of Risks},
author = {Landi, Antonio and Branca, Mattia and Vranckx, Pascal and Leonardi, Sergio and Frigoli, Enrico and Heg, Dik and Calabro, Paolo and Esposito, Giovanni and Sardella, Gennaro and Tumscitz, Carlo and Garducci, Stefano and Andò, Guiseppe and Limbruno, Ugo and Sganzerla, Paolo and Santarelli, Andrea and Briguori, Carlo and Torre Hernández, José María de la and Pedrazzini, Giovanni and Windecker, Stephan and Marco Valgimigli and MATRIX Investigators},
}